Hyperuricemia and Cardiovascular Risk: Insights and Implications

Area of Science:

• Cardiology and Nephrology
• Metabolic Disorders

Background:

• Hyperuricemia, defined by elevated serum uric acid, is increasingly prevalent globally.
• It is associated with multiple cardiovascular diseases, including hypertension, heart failure, and coronary artery disease.
• Mechanisms linking hyperuricemia to cardiovascular risk involve inflammation, oxidative stress, and endothelial dysfunction.

Purpose of the Study:

• To review the complex relationship between hyperuricemia and cardiovascular diseases.
• To evaluate the role of urate-lowering therapies in managing cardiovascular risk.
• To discuss the implications for clinical practice and future research directions.

Main Methods:

• Comprehensive literature review of major cardiovascular and hyperuricemia studies (e.g., Framingham Heart Study, CARES, FAST).
• Analysis of mechanisms linking elevated uric acid to cardiovascular pathology.
• Examination of evidence for urate-lowering therapies and conflicting trial results.

Main Results:

• Hyperuricemia is associated with increased cardiovascular risk, mediated by inflammation and endothelial dysfunction.
• Conflicting evidence exists regarding the cardiovascular benefits and safety of urate-lowering therapies (e.g., febuxostat vs. allopurinol).
• The causal role of hyperuricemia versus its function as a risk marker is still debated.

Conclusions:

• Clinical management of hyperuricemia in cardiovascular disease requires individualized risk assessment.
• Further research is needed to clarify hyperuricemia's causal role and optimize treatment strategies.
• Integrating uric acid levels into cardiovascular risk scores may improve patient stratification.